Agenus Inc. and Noetik have announced a new collaboration to develop AI-enabled predictive biomarkers for the immuno-oncology combination of botensilimab and balstilimab. This partnership aims to accelerate precision immunotherapy by leveraging Noetik's virtual cell models and extensive tumor data. The collaboration builds on a 2024 Cancer Discovery study highlighting botensilimab's unique immune activation mechanisms. By integrating AI technologies with clinical data, the initiative seeks to identify predictive biomarkers, improve trial success, and enhance patient outcomes, aligning with national priorities for personalized cancer treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.